PR: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
Ladenburg, Germany, 5 April 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that it will be hosting an R&D Webinar on 23 April 2024 at 16.00 CEST/15.00 BST, for investors, analysts and media.
The R&D webinar will feature presentations from Heidelberg Pharma’s management team, alongside leading Key Opinion Leaders (KOLs) in the ADC field, Rakesh Dixit, PhD, CEO of Bionavigen, Gaithersburg, USA, and Jonathan Kaufman, MD, Associate Professor of Hematology & Medical Oncology, Emory University School of Medicine, Atlanta, USA.
The event will provide information on Heidelberg Pharma’s lead clinical ATAC product candidate HDP-101 targeting relapsed and refractory multiple myeloma as well as its proprietary ADC toolbox and therapeutic product pipeline. A clinical presentation of first efficacy data from the Phase I/IIa clinical trial with HDP-101 will take place at the upcoming American Association for Cancer Research (AACR) Annual Meeting, San Diego, California from 5 to 10 April 2024.
Attendees will have the opportunity to participate in a live Q&A session at the end of the presentation or submit questions in advance of the event.
For further information on the R&D webinar, or to register your interest, please contact Optimum Strategic Communications at
https://stream.brrmedia.co.uk/broadcast/65fda77d45e3d218036ff838
A live recording of the R&D webinar will be accessible via the press & investor section of the Company website shortly after the event or on https://brrmedia.news/HP_IS24.